Invivyd
IVVD | NASDAQ
$0.54
-$0.04 (-7.23%)
At close: Nov 16, 2026, 4:00 PM ET
$0.56
+$0.02 (+3.67%)
After-hours:
Nov 16, 2026, 7:54 PM ET
Invivyd Company Profile
Company profile explainedCompany Profile
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Marc William Elia | CEO & Chairperson of the Board |
| Jill Andersen | Chief Legal Officer & Corporate Secretary |
| Julie Green | Chief Human Resources Officer |
| Katie Falzone | Senior Vice President of Finance |
| Kristie Coneys Kuhl | Chief Communications Officer |
| Michael J. Mina | Chief Medical Officer & Chief Epidemiologist |
| Rachael Gerlach | Senior Vice President of Regulatory Affairs |
| Robert D. Allen | Chief Scientific Officer |
| Timothy Lee | Chief Commercial Officer |
| William E. Duke Jr. | CFO and Principal Financial & Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 3 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
Invivyd
| Country | United States |
| IPO Date | Aug 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 122 |
| CEO | Marc William Elia |
Contact Details
209 Church Street New Haven,
Connecticut 06510 United States
Stock Details
| Ticker Symbol | IVVD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001832038 |
| CUSIP Number | 00534A102 |
| ISIN Number | US00534A1025 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove IVVD